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In the event of smallpox bioterrorism, widespread vaccination may be required. Vaccinia immune globulin (VIG) has been used to treat
complications from the smallpox vaccine. While the potency of VIG was defined by its ability to neutralize intracellular mature virus, a
second form of vaccinia called the extracellular enveloped virus (EEV) is critical for virus spread in the host. The B5R-protein is one of many
EEV-specific proteins. Immunoprecipitation and ELISA revealed that VIG recognizes the B5R-protein. An EEV plaque-reduction assay
using a recombinant vaccinia that lacks the majority of the extracellular domain of B5R showed that the ability of VIG to neutralize EEV is
principally directed at B5R. In addition, absorbing out the anti-B5R antibody present in VIG through the addition of recombinant B5R
protein abrogated VIG’s ability to significantly neutralize wild-type EEV. This work demonstrates the prominent role of B5R as a target of
EEV-neutralizing activity of human antibodies.
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Neutralization tests
Introduction ing plasma for VIG preparation. Given the fact that routineConcerns about the intentional release of variola virus has
led to the possibility of widespread vaccination with vaccinia
virus. The primary treatment for vaccinia vaccine complica-
tions would be vaccinia immune globulin (VIG). While
never tested in randomized clinical trials, VIG is believed
to be effective in treating complications resulting from
vaccinia virus vaccination (Barbero et al., 1955; Kempe et
al., 1956; Sussman, 1965). VIG is prepared by cold ethanol
fractionation of plasma obtained from multiple donors who
were recently vaccinated with vaccinia virus. In prior deca-
des, the donors may have been previously vaccinated as
children, and then revaccinated a few weeks before provid-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.05.004
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E-mail address: isaacs@mail.med.upenn.edu (S.N. Isaacs).vaccinia virus vaccination ended in the United States in the
early 1970s, current VIG stocks are being prepared from
donors who are vaccinated once, approximately 2 weeks
before plasmaphoresis. The potency of VIG was defined by
its ability to neutralize intracellular mature virus (IMV).
However, a second form of vaccinia virus known as the
extracellular enveloped virus (EEV) is critical for virus
spread in the host (Payne, 1980; Smith and Vanderplasschen,
1998). The B5R protein is one of many EEV-specific
proteins that are vital for the optimal formation of EEV
(Engelstad and Smith, 1993; Engelstad et al., 1992; Isaacs et
al., 1992; Wolffe et al., 1993). While it has been shown that
the B5R protein is an important target of EEV neutralizing
antibodies (Galmiche et al., 1999; Hooper et al., 2003; Law
and Smith, 2001), here we show that human immune
globulin used as a therapeutic agent to treat complications
from vaccinia virus vaccination contains a high titer of
antibodies that recognize B5R and, using a recombinant
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domain of the B5R protein, we demonstrate that the ability of
VIG to neutralize EEV is mainly directed against B5R. This
finding more clearly defines the role of B5R as a critical
target of EEV neutralizing antibody than has been suggested
by previous work (Law and Smith, 2001) using hyperim-
mune vaccinia globulin obtained from a vaccinated rabbit.Results
VIG recognizes B5R by immunoprecipitation and ELISA
Using a previously constructed recombinant vaccinia
virus that expresses a secreted soluble B5R protein (Isaacs
et al., 1992), we demonstrated that VIG recognized B5R
secreted into the media of infected cells by immunoprecipi-
tation (Fig. 1A). Direct ELISA demonstrated high-titer anti-
B5R antibodies present in VIG (Fig. 1B). Strong reactivity
(O.D. V 1) with recombinant vaccinia virus produced solu-
ble-secreted B5R, bacterial-produced B5R, and baculovirus-
produced B5R was obtained with VIG at a dilution of
1:25600 (0.39 Ag; Fig. 1B). In contrast, control Ig had
reactivity with the bound proteins at only a 1:800 dilution
(12.5 Ag). The low reacti-vity of control pooled human
immune globulin with vaccinia virus proteins on immuno-
precipitation and ELISA is likely due the fact that this pooled
immune globulin likely contains immune globulin from some
donors who had been previously vaccinated with vaccinia
virus (Goldsmith et al., 2004).
VIG neutralizes EEV mainly by targeting B5R
The outer membrane of EEV is considered to be quite
fragile and thus harsh manipulations like freeze-thawing or
even prolonged storage at 4 jC results in release of the
equally infectious IMV. Therefore, assays to examine EEVFig. 1. Reactivity of VIG with B5R. (A) Immunoprecipitations were performed wit
contain B5R or with media from a recombinant vaccinia virus that secretes a s
detected using an anti-B5R rabbit antibody (Isaacs et al., 1992). Lane 1, VIG with
control-Ig with WT media; lane 5, control-Ig with sB5R; lane 6, beads with sB5R. N
ELISA of dilutions of VIG (closed symbols, solid lines) and control Ig (open
(squares), and bacteria-produced B5R (circles).neutralization were carried out with fresh EEV incubated
along with a potent IMV-neutralizing antibody 2D5 (Ichiha-
shi et al., 1994) to neutralize any contaminating IMV. VIG at
1.5 mg/ml results inf81% neutralization of wild-type EEV
(vaccinia virus strain IHDJ), while the same concentration of
control human Ig has no effect (Fig. 2A). This sensitivity of
wild-type EEV to neutralization by VIG is in contrast to a
mutant vaccinia virus that lacks approximately 80% of the
extracellular domain of the B5R protein, which is resistant to
neutralization by VIG (Fig. 2B). As further evidence that the
ability of VIG to neutralize EEV is largely due to B5R, we
competed out anti-B5R antibodies from VIG by incubating
VIG with recombinant B5R protein before adding VIG to the
EEV neutralization assay. When recombinant baculovirus-
produced B5R protein (Earl et al., 2004) is included (100 Ag/
ml), VIG was only able to neutralize approximately 20% of
wild-type EEV (Fig. 2C). Importantly, this loss of EEV
neutralizing activity is not caused by a nonspecific alteration
of the VIG due to the addition of a baculovirus-produced
protein. When we added an irrelevant baculovirus-produced
protein (herpes simplex virus extracellular domain of gD;
Rux et al., 1998) to VIG, it did not alter VIG’s ability to
neutralize EEV (Fig. 2C). Because a previously published
study (Law and Smith, 2001) using aWR-based recombinant
vaccinia virus lacking approximately 80% of the ectodomain
of the B5R protein (Herrera et al., 1998) and hyperimmune
rabbit immune globulin gave a different result, we also
examined EEV neutralization of this WR-based virus by
VIG (Fig. 3D). Similar to the IHDJ-based virus lacking all
four SCR domains (Fig. 3B), the WR-based virus was also
relatively resistant to neutralization by human VIG, indicat-
ing that our findings were not vaccinia-strain specific. In
addition, to ensure that our findings using VIG (Baxter)
obtained from the CDC were not brand- or lot-specific, we
found similar EEV neutralization activity with a different
source of VIG (VIG-IV, Reference vaccinia immune globu-
lin) obtained from the FDA (Fig. 3).h media from cells infected with wild-type (WT) vaccinia virus that does not
oluble form of B5R (sB5R). Successful immunoprecipitation of B5R was
WT media; lane 2, VIG with sB5R; lane 3, beads with WT media; lane 4,
umbers on the left refer to the molecular masses (in kilodaltons). (B) Direct
symbols, broken lines) with sB5R (triangles), baculovirus-produced B5R
Fig. 2. EEV neutralization by VIG. EEV from cells infected with wild-type virus (A) or from the mutant virus lacking the majority of the extracellular domain
of B5R (B) were incubated in the presence of a potent IMV-neutralizing monoclonal antibody along with no antibodies (gray bars), control pooled Ig (Con-Ig;
hatched bars), or VIG (black bars) and the resulting titer was determined by serial dilutions. Data was normalized to an input virus of 3000 pfu and represents
the mean of five independent experiments for each condition. Wilcoxon rank sum test used for comparison between each control Ig and VIG condition, (A) P =
0.009 and (B) P > 0.5, both two-tailed. When recombinant-soluble rB5R baculovirus-produced protein (rB5R; 10 Ag/sample) was included during incubation
(C), the ability of VIG to neutralize wild-type EEV was significantly reduced, while addition of a control baculovirus-produced protein (gD) did not affect
VIG’s ability to neutralize EEV. + and  refer to the addition or absence of VIG or control Ig (Con-Ig) or the addition or absence of soluble gD or rB5R. Data
represents the mean of three independent experiments for each condition. Student’s t test used for comparison between VIG alone and VIG with gD (P = 0.29)
or VIG with rB5R (P = 0.009), both two-tailed.
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While direct neutralization of released virus is one way,
antibodies can help control orthopoxvirus infections; inhibi-
ting the release of virus from infected cells is anotherFig. 3. Comparison of neutralization of EEV from strains IHDJ and WR by VIG.
mutant virus lacking the majority of the extracellular domain of B5R, strain IHDJ
mutant virus lacking the majority of the extracellular domain of B5R, strain WR
antibody along with no antibodies (gray bars), or FDA Reference VIG-IV (black ba
the mean of three to four independent experiments for each condition. Student’s t t
P = 0.003, (B) P = 0.15, (C) P = 0.004, and (D) P = 0.59, all two-tailed.potential mechanism. When grown in a cell monolayer
under liquid media, vaccinia virus (strain IHDJ) generates
a characteristic plaque phenotype called comets (Fig. 4A)
due to the release of EEV from infected cells and spread to
distant cells (Appleyard et al., 1971; Law et al., 2002).EEV from cells infected with wild-type virus, strain IHDJ (A), or from the
(B), or from cells infected with wild-type virus, strain WR (C), or from the
, were incubated in the presence of a potent IMV-neutralizing monoclonal
rs) and the resulting titer was determined by serial dilutions. Data represents
est used for comparison between no antibody and VIG-IV in each panel (A)
Fig. 4. Plaque phenotypes in the presence and absence of antibodies. Vaccinia virus (strain IHDJ) generates a characteristic comet phenotype when grown in
monolayers overlaid with liquid media (A, D) and in the presence of control Ig (250 Ag/ml; B, E). However, comet formation is appreciably inhibited in the
presence of VIG (250 Ag/ml; C, F). Wild-type vaccinia virus (A, B, C); I-B5RDSCR1– 4 (D, E, F).
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virus lacking the majority of the extracellular domain of the
B5R protein (Herrera et al., 1998) (Fig. 4D). In the presence
of control Ig, there is a slight alteration in comets, but
comets are still formed (Fig. 4B,E). However, the comet
phenotype is appreciably inhibited in the presence of VIG in
cells infected with either the wild-type (Fig. 4C) or mutant
virus lacking the extracellular domain of the B5R protein
(Fig. 4F). This indicates that VIG has targets that inhibit
comet formation that are independent of B5R protein.Discussion
Recent data (Hammarlund et al., 2003) suggests that
vaccination against smallpox with vaccinia virus leads to
long-lasting immunity that protects from death. These data
also highlight the apparent importance of antibody
responses as a correlate of immunity. Therefore, a more
thorough understanding of VIG, a product successfully used
to treat complications from vaccinia virus vaccination and
for prophylaxis after smallpox exposure (Barbero et al.,
1955; Kempe et al., 1956; Sussman, 1965), is warranted.
One would expect that important antibody responses would
be directed at the surface proteins found on the two main
forms of infectious virus, IMVand EEV. IMVenters the cell
in a pH-independent fusion at the cell membrane and VIG is
quite potent at neutralizing IMV. EEV is thought to gain
entry into the cell through an endocytic pathway that
requires acidification (Vanderplasschen et al., 1998a). This
may explain why EEV is more difficult to neutralize. Oncein the acidic environment of the endosome, the fragile outer
membrane of EEV is disrupted, releasing the equally infec-
tious IMV, which can then enter the cell in an environment
where IMV-neutralizing antibodies are no longer effective.
Thus, understanding the targets of EEV-neutralizing anti-
bodies will be important for the development of more
effective antibody therapies directed at poxvirus infections
as well as the development of safer smallpox vaccines.
The B5R protein is an important target of EEV neu-
tralizing antibodies (Galmiche et al., 1999; Hooper et al.,
2003; Law and Smith, 2001). B5R is a type I membrane
protein with a large extracellular domain composed of
regions with similarity to short consensus repeat (SCR)
domains of complement regulatory proteins (Engelstad
et al., 1992). While no complement regulatory activity
has been attributed to this protein (Vanderplasschen et al.,
1998b), the B5R protein is involved in the wrapping steps
of IMV that ultimately form EEV. The SCR domains of
the B5R protein are not required for EEV formation
(Herrera et al., 1998; Mathew et al., 1998) and we used
a recombinant vaccinia virus lacking the four SCR
domains to characterize VIG’s ability to neutralize EEV.
Our results showing that this mutant virus lacking the SCR
domains is resistant to neutralization by vaccinia-immune
polyclonal human IgG differs from a report using vaccinia-
immune polyclonal rabbit IgG (Law and Smith, 2001). The
authors of that paper concluded that EEV neutralization by
hyperimmune globulin had multiple targets and the lack of
any one EEV-specific protein did not result in the ability of
virus to completely escape neutralization. Furthermore,
they showed that the recombinant vaccinia virus lacking
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with hyperimmune rabbit globulin while we show that this
virus is resistant to neutralization by human VIG. The
reason for the discrepancy is unclear. A likely ex-
planation is that their work was with hyperimmune IgG
obtained from a single rabbit boosted multiple times over a
3-month period with 2  107 pfu of vaccinia virus (strain
WR), whereas we studied VIG, pooled sera that had been
collected from many humans recently vaccinated once with
Dryvax. Thus, there may be a difference in the quality and
targets of the antibody response developed in rabbits vs.
humans under these different vaccination sche-
dules. Although Law and Smith used a WR-based recom-
binant vaccinia virus lacking the B5R extracellular domain
that we generated (Herrera et al., 1998), this virus when
incubated with VIG performs similarly to the IHDJ-based
virus that we focused on in this report. Similar to Law &
Smith, we used the same cell line to generate EEV. Other
potential explanations for the differences in the two studies
include that our assays looked to neutralize 20 times more
EEV than they used in their assays (i.e., approximately
3000 input pfu in our assay vs.150 pfu in their assay).
Consequently, we used a higher concentration of immune
globulin in our assays (i.e., 1500 Ag/ml in our assay vs.
100 Ag/ml in their assay). So perhaps our assay is more
sensitive to neutralization via cross-linking and aggregation
of virus. In support of the central role of B5R as a target
of EEV neutralizing antibody that we report here, Law and
Smith show that antibodies raised to B5R could fully
neutralize wild-type EEV to a level similar to hyperim-
mune vaccinia virus IgG (Law and Smith, 2001). Thus, we
believe that this data supports our conclusion that anti-
bodies directed at B5R that form during vaccination are
mainly responsible for EEV neutralization. Because EEV is
important for orthopoxvirus pathogenesis, the B5R protein
will likely be a key therapeutic target for future antibody
therapies or new subunit or DNA vaccines directed against
smallpox (Galmiche et al., 1999; Hooper et al., 2003,
2004).
While the ability of VIG to neutralize EEV is directed at
B5R, using the comet inhibition assay as an in vitro measure
of the release of EEV from infected cells, we found that VIG
could inhibit comet formation independent of the presence
or absence of the majority of the extracellular domain of the
B5R protein. Thus, the humoral immune response generated
by vaccinia virus vaccination has additional targets that can
limit the spread of infection. That is, while some antibodies
may not be able to neutralize free EEV, antibodies to EEV-
specific proteins may prevent release of EEV from infected
cells. This may be a mechanism by which antibodies raised
against the EEV-specific proteins that fail to neutralize EEV
confer protection in animal models (Galmiche et al., 1999).
It is unknown whether EEV neutralizing activity or comet
inhibition activity is more important for protection, but
some data (Galmiche et al., 1999) suggest that either activity
can be equally protective.Materials and methods
Viruses
Freshly prepared EEV was obtained from serum-free
media (Opti-MEM) of RK-13 cells infected for 48 h with
vaccinia virus [International Health Department Strain-J
(IHDJ)] or with a previously described recombinant vaccinia
virus vSI-26 (I-B5RDSCR1–4) (Herrera et al., 1998). I-
B5RDSCR1–4 is an IHDJ-based recombinant virus that lacks
206 residues of its 257 amino acid B5R extracellular domain,
but produces near wild-type levels of EEV (Herrera et al.,
1998). The harvested media containing EEVwas kept at 4 jC
and used within 1–2 weeks after initial infection. Titers of
EEV in such media (in the presence of anti-IMV neutralizing
antibody) were routinely approximately 106 plaque-
forming units (pfu)/ml. In a similar fashion, EEV from
vaccinia virus Western Reserve (WR) and vSI-22, a pre-
viously described WR-based mutant virus lacking the B5R-
ectodomain (W-B5RDSCR1–4) (Herrera et al., 1998), were
prepared from RK-13 cells.
Antibodies
The anti-IMV neutralizing monoclonal antibody, 2D5
(Ichihashi et al., 1994), directed at the vaccinia virus L1R
protein (Wolffe et al., 1995), was used at a 1:1000 dilution, a
dilution that is able to neutralize 4–5 log10 of IMV. Two
sources of Vaccinia immune globulin (VIG) were used. VIG
(Baxter; 165 mg/ml; Lot No. 0448A101AA) was obtained
from the CDC and VIG-IV (Reference vaccinia immune
globulin; 50 mg/ml; Lot 1) was obtained from the FDA.
Control pooled human immune globulin (Ig) used was
Polygam (Red Cross; 100 mg/ml).
Immunoprecipitations
Serum-free media from cells infected with wild-type
vaccinia virus or a previously described virus, vSI-13 (Isaacs
et al., 1992), were used in immunoprecipitations. vSI-13 is a
recombinant vaccinia virus that expresses a mutated version
of the B5R open reading frame with a stop codon just before
the transmembrane domain that results in the secretion of the
extracellular domain of the B5R protein into the media. Two
microliters of this media or 10 Al of media from cells infected
with wild-type virus (that does not secrete B5R) were
incubated with 250 Ag/ml of VIG or control Ig at 4 jC
overnight. Protein G beads were then added and incubated
for 2 h at room temperature. After washing, the beads were
boiled in Laemmli loading buffer and run on a 0.1% SDS–
16% PAGE gel. Proteins were transferred to PVDF mem-
brane. The membrane was blocked with 10% nonfat milk in
PBS for 2 h at room temperature, washed three times with
PBS containing 0.1% Tween 20, and then incubated with a
previously described (Isaacs et al., 1992) anti-B5R rabbit
antibody (1:5000). After three washes, the blot was incubat-
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for 1 h and immunoreactive bands were visualized by
chemiluminescence.
Enzyme-linked immunosorbent assay (ELISA)
A direct anti-B5R ELISA was carried out in parallel on
recombinant B5R from three sources: the vaccinia virus
expressed soluble B5R protein (sB5R) (Isaacs et al., 1992)
described earlier, a GST-fusion protein expressed in Escheri-
chia coli (bact-B5R; Shamim and Isaacs, unpublished), and
a His-tagged B5R protein expressed in baculovirus (baculo-
B5R; (Earl et al., 2004)). Ninety-six-well microtiter ELISA
plates were coated with 5 Al/ml of sB5R or 10 Ag/ml of
either bact-B5R or baculo-B5R in coating buffer, incubated
overnight at 4 jC, and then blocked with 2% nonfat milk in
PBS for 2 h. Serial dilutions of VIG and control human Ig
(both at 100 mg/ml and starting at 1:400 dilution and out to
1:51,200) were added to wells, incubated for 1 h at 37 jC,
and washed with PBS containing 0.05% Tween 20. Bound
antibody was detected with HRP-conjugated goat antihuman
antibody (1:10,000) and chromogen orthophenylenediamine
(1 mg/ml) in 50 mM citrate buffer (pH 5.0) at 490 nm.
EEV neutralization assay
The assay was carried out in a final volume of 100 Al with
an input of approximately 3000 pfu of EEV in serum-free
media along with anti-IMV neutralizing monoclonal anti-
body 2D5 (1:1000 final concentration) with or without 150
Ag of immune globulins (VIG or control Ig). Samples were
incubated for 1–2 h at 37 jC and then infectious virus was
titered by serial dilutions. Dilutions were added to mono-
layers of BSC-1 cells and incubated for 2 h at 37 jC in a 5%
CO2 atmosphere. The inoculum was removed, the wells
overlaid with media containing 2.5% heat-inactivated FBS
and 1% carboxymethylcellulose, and plates were incubated
for approximately 2 days. The overlay was removed, the
cells stained with 0.1% crystal violet, and the plaques were
counted.
Comet inhibition assay
Confluent BSC-1 cells were infected with vaccinia virus
(strain IHDJ) and approximately 2 h postinfection, the
inoculum was removed and replenished with fresh serum-
free media containing 250 Ag/ml of VIG or control Ig. Plates
were incubated for 36 h and then stained with crystal violet.
This assay was performed on multiple occasions and repre-
sentative wells were photographed.Acknowledgments
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